Sacituzumab govitecan in HR(+)HER2(-) metastatic breast cancer: the randomized phase 3 EVER-132-002 trial
Sacituzumab govitecan 治疗 HR(+)HER2(-) 转移性乳腺癌:随机 3 期 EVER-132-002 试验
期刊:Nature Medicine
影响因子:50
doi:10.1038/s41591-024-03269-z
Xu, Binghe; Wang, Shusen; Yan, Min; Sohn, Joohyuk; Li, Wei; Tang, Jinhai; Wang, Xiaojia; Wang, Ying; Im, Seock-Ah; Jiang, Dongdong; Valdez, Theresa; Dasgupta, Anandaroop; Zhang, Yiran; Yan, Yilin; Komatsubara, Kimberly M; Chung, Wei-Pang; Ma, Fei; Dai, Ming-Shen